|
|
Vaccine Detail
|
MVA-EBNA1/LMP2 Vaccine |
| Vaccine Information |
- Vaccine Name: MVA-EBNA1/LMP2 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007545
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- EBNA-1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Hui et al., 2013)
- Detailed Gene Information: Click Here.
- PSMB9
gene engineering:
- Type: Recombinant protein preparation
- Description: (Hui et al., 2013)
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the gene for the CD4 epitope-rich C-terminal domain of the Epstein Barr Virus (EBV) antigen EBNA1 and fused to the full-length of the EBV-associated antigen latent membrane protein 2 (LMP2), with potential immunostimulatory and antineoplastic activities. Upon administration, MVA EBNA1/LMP2 vaccine may elicit a cytotoxic T-cell immune response against cancer cells expressing EBNA1 and LMP2. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation. (NCIT_C91076).
|
| Host Response |
|
|
| References |
Hui et al., 2013: Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, Stocken DD, Rickinson AB, Steven NM, Chan AT. Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer research. 2013; 73(6); 1676-1688. [PubMed: 23348421].
NCIT_C91076: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91076]
|
|
